Medtronic plc, a global leader in healthcare technology, will spotlight the latest innovations in deep brain stimulation (DBS) at the International Congress of Parkinson’s Disease and Movement Disorders® (MDS Congress) in Philadelphia, Pennsylvania, September 27 to October 1, 2024.

2024年9月27日至10月1日，在宾夕法尼亚州费城举行的帕金森病和运动障碍国际大会（MDS Congress）上，医疗保健技术的全球领导者美敦力公司（Medtronic plc）将重点介绍深部脑刺激（DBS）的最新创新。

Medtronic will host a special interactive session to demonstrate real-world application of its exclusive BrainSense™ technology. The symposium features Medtronic DBS patient, Brandan Mehaffie; his neurologist, Dr. Sol De Jesus, Chief of the Movement Disorders Division, Penn State Health; and implanting neurosurgeon, Dr.

美敦力将举办一场特别的互动会议，展示其独家BrainSense™技术的真实应用。研讨会的特点是美敦力DBS患者Brandan Mehaffie；他的神经科医生，宾夕法尼亚州立卫生大学运动障碍科科长Sol De Jesus博士；并植入神经外科医生，博士。

James McInerney, Professor of the Department of Neurosurgery, Penn State Health who will demonstrate how Brandan’s Percept™ PC neurostimulator with BrainSense™ works to manage his Parkinson’s symptoms..

宾州州立卫生大学神经外科教授詹姆斯·麦金纳尼（JamesMcInerney）将演示布兰登（Brandan）的Percept™PC神经刺激器和BrainSense™如何控制帕金森氏症症状。。

In addition, Medtronic Brain Modulation research and clinical experts will join neurologist, Dr. Todd Herrington, Director of the Deep Brain Stimulation Program, Mass General Hospital to present key lessons learned from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial.

此外，美敦力大脑调节研究和临床专家将与神经学家、麻省总医院深部脑刺激计划主任托德·赫林顿博士一道，介绍自适应DBS算法在帕金森病个性化治疗（ADAPT-PD）试验中取得的关键经验教训。

The ADAPT-PD trial is a global, multi-center, prospective, single-blind, and randomized crossover study developed to evaluate the safety and effectiveness of chronic dual and single threshold adaptive deep brain stimulation† (aDBS) modes (as compared to continuous DBS) across all PD patients eligible for DBS.

ADAPT-PD试验是一项全球性，多中心，前瞻性，单盲和随机交叉研究，旨在评估慢性双阈值和单阈值自适应深部脑刺激†（aDBS）模式（与连续DBS相比）的安全性和有效性）所有符合DBS条件的PD患者。

Adaptive DBS (aDBS) is investigational and is not approved by the Food and Drug Administration (FDA) for commercialization in the United States (US). In the US, the safety and effectiveness of aDBS has not been established. aDBS is investigational and not available for commercial distribution in Europe.

自适应DBS（aDBS）是一种研究性产品，未经美国食品和药物管理局（FDA）批准在美国（US）商业化。在美国，ADB的安全性和有效性尚未确定。ADB是研究性的，不可在欧洲进行商业分销。

The Medtronic Adaptive DBS feature is only approved in Japan..

美敦力自适应DBS功能仅在日本获得批准。。

“We are excited to showcase our latest groundbreaking research and innovation at the 2024 Movement Disorder Society Congress,” said Rob Raike, PhD, director of Medtronic Neuromodulation Research and Technology, which is part of the Neuroscience Portfolio at Medtronic. “This Congress is an important forum for scientific exchange and underscores the criticality of academic and industry partnership.

“我们很高兴在2024年运动障碍学会大会上展示我们最新的突破性研究和创新，”美敦力神经调节研究与技术总监Rob Raike博士说，该研究与技术是美敦力神经科学投资组合的一部分。“这次大会是一个重要的科学交流论坛，强调了学术和工业合作的重要性。

For more than 30 years, Medtronic has been committed to advancing the clinical and scientific discipline of movement and other neurological disorders and we remain deeply invested in the advancement of DBS therapy.”.

30多年来，美敦力一直致力于推进运动和其他神经系统疾病的临床和科学学科，我们仍然对DBS治疗的进步进行了深入投资。”。

Medtronic will have key Neuromodulation executives on-site including Amaza Reitmeier, vice president and general manager, Brain Modulation; Paolo Di Vincenzo, president, Neuromodulation; Robert Raike, PhD, director, Neuromodulation Research and Technology; Dara Polnerow, senior director, training and education; Kimberly Thomas-Pollei, PhD, Neuromodulation; and Jason Fiepel, senior product development director, Brain Modulation..

美敦力将有关键的神经调节高管在场，包括大脑调节副总裁兼总经理Amaza Reitmeier；保罗·迪文森佐，神经调节总裁；Robert Raike博士，神经调节研究与技术总监；Dara Polnerow，培训和教育高级总监；Kimberly Thomas Pollei博士，神经调节；和Jason Fiepel，Brain Modulation高级产品开发总监。。

Attendees can explore the future of DBS at the Medtronic Innovation Tech Suite, which is behind the Medtronic exhibit booth #813. Additional details about Medtronic at the MDS Congress are listed below:

与会者可以在美敦力创新技术套房探索星展的未来，该套房位于美敦力展台#813的后面。美敦力在MDS大会上的其他详细信息如下：

Medtronic Sponsored Symposium

美敦力赞助的研讨会

“Real-world application of DBS BrainSense™ technology – The clinical journey” – innovation showcase symposium featuring live patient demonstration

“DBS BrainSense™技术的真实应用-临床之旅”-以患者现场演示为特色的创新展示研讨会

Date: Monday, September 30, 2024

日期：2024年9月30日，星期一

Time: 10:00-10:30 a.m. Eastern Time (ET)

时间：东部时间上午10:00-10:30（东部时间）

Location: MDS Pavilion – Exhibit Hall A (2nd level of the PA Convention Center)

地点：MDS展馆-展览厅A（PA会议中心二楼）

Medtronic Abstracts & Oral Presentations

美敦力摘要和口头报告

The following scientific abstracts and oral presentations represent the work of Medtronic employees and independent investigators using Medtronic technology in their research.

以下科学摘要和口头陈述代表了美敦力员工和独立研究人员在研究中使用美敦力技术的工作。

Programming adaptive deep brain stimulation in the clinic: lessons from the ADAPT-PD trial. Todd Herrington, Martijn Beudel, Jill Ostrem, Simon Little, Leonardo Almeida, Adolfo Ramirez-Zamora, Alfonso Fasano, Travis Hassell, Kyle Mitchell, Elena Moro, Michal Gostkowski, Nagaraja Sarangmat, Scott Stanslaski, Lisa Tonder, Ye Tan, Rebekah Summers, Tim Goble, Robert Raike, Helen Bronte-Stewart.

在临床上编程自适应深部脑刺激：ADAPT-PD试验的经验教训。托德·赫林顿、马丁·比德尔、吉尔·奥斯特姆、西蒙·利特尔、莱昂纳多·阿尔梅达、阿道夫·拉米雷斯·萨莫拉、阿方索·法萨诺、特拉维斯·哈塞尔、凯尔·米切尔、埃琳娜·莫罗、迈克尔·戈斯特科夫斯基、长加拉加·萨兰马特、斯科特·斯坦斯拉斯基、丽莎·托德、叶坦、丽贝卡·萨默斯、蒂姆·戈布尔、罗伯特·莱克、海伦·勃朗特·斯图尔特。

Featured on Saturday, September 28 at 1:30 – 2:30 p.m. ET via Oral Platform Presentation Group 1: Clinical Trials

美国东部时间9月28日星期六下午1:30–2:30通过口头平台演示第1组：临床试验

Monopolar sensing improves the efficiency of DBS programming in Parkinson’s disease. John Thompson, Erin Radcliffe, Steven Ojemann, Daniel Kramer, Michelle Case, Caleb Zarns, Abbey Holt-Becker, Robert Raike, Alexander Baumgartner, Drew Kern

单极感应提高了帕金森病DBS编程的效率。约翰·汤普森（JohnThompson）、艾琳·拉德克利夫（ErinRadcliffe）、史蒂文·奥杰曼（StevenOjemann）、丹尼尔·克莱默（DanielKramer）、米歇尔·凯斯（MichelleCase）、卡莱布·赞恩斯（CalebZarns）、艾比·霍尔特·贝克尔（AbbeyHoltBecker）、罗伯特·雷克（Robe

Correlation of neural sensing with the volume of neural activation within the desired patient-specific anatomical target in deep brain stimulation for Parkinson’s disease. Michelle Case, Caleb Zarns, Abbey Holt-Becker, Robert Raike, Erin Radcliffe, John Thompson, Drew Kern

在帕金森氏病的深部脑刺激中，神经传感与所需患者特定解剖目标内神经激活量的相关性。米歇尔·凯斯、卡莱布·赞斯、艾比·霍尔特·贝克尔、罗伯特·雷克、艾琳·拉德克利夫、约翰·汤普森、德鲁·科恩

Comparison of monopolar and bipolar sensing of beta frequency in Parkinson’s disease of the subthalamic nucleus for deep brain stimulation. Drew Kern, Erin Radcliffe, Steven Ojemann, Daniel Kramer, Michelle Case, Caleb Zarns, Abbey Holt-Becker, Robert Raike, Alexander Baumgartner, John Thompson

丘脑底核帕金森病患者大脑深部刺激的单极和双极β频率感应的比较。德鲁·科恩、艾琳·拉德克利夫、史蒂文·奥杰曼、丹尼尔·克莱默、米歇尔·凯斯、卡莱布·赞恩斯、艾比·霍尔特·贝克尔、罗伯特·雷克、亚历山大·鲍姆加特纳、约翰·汤普森

Comparing ring and directional globus pallidus stimulation effects on Parkinson’s gain. Anjanibhargavi Ragothaman, Zachary Nhem, Graham Harker, Patricia Carlson-Kuhta, Lee Neilson, Caleb Zarns, Michelle Case, Abbey Becker, Robert Raike, Kim Burchiel, Martina Mancini, Delaram Safarpour

比较环状和定向苍白球刺激对帕金森氏增益的影响。

Case studies of real-world brain sensing showing patient-specific trends to inform therapy management in Parkinson’s disease. Amin Nourmohammadi, Elizabeth Fehrmann, Abbey Holt-Becker, Robert Raike

现实世界大脑感知的案例研究显示了患者特定的趋势，为帕金森病的治疗管理提供了信息。阿明·努尔莫哈马迪、伊丽莎白·费尔曼、艾比·霍尔特·贝克尔、罗伯特·雷克

Real-world Programming and Sensing from Adaptive Deep Brain Stimulation for Parkinson’s Disease in Japan. Genko Oyama, Katsuo Kimura, Haruhiko Kishima, Nagako Murase, Yoshio Tsuboi, Takashi Tsuboi, Tatsuya Takezaki, Yoshinori Higuchi, Takao Hashimoto, Yasushi Shimo, Thomas C. Brionne, Isabelle Buffin, Kazuhiro Hidaka, Filippo Coletti, Roy Amit, Nathan Morelli, Hideo Mure and Hideki Oshima.

日本帕金森氏病自适应深部脑刺激的现实编程和感知。Genko Oyama、Katsuo Kimura、Haruhiko Kishima、Nagako Murase、Yoshio Tsuboi、Takashi Tsuboi、Tatsuya Takezaki、Yoshinori Higuchi、Takao Hashimoto、Yasushi Shimo、Thomas C.Brionne、Isabelle Buffin、Kazuhiro Hidaka、Filippo Coletti、Roy Amit、Nathan Morelli、Hideo Mure和Hideki Oshima。

The globally recognized MDS Congress is held during a year of significant advancements from Medtronic Brain Modulation, including the U.S. Food & Drug Administration (FDA) and CE (Conformité Européenne) Mark approvals of the Medtronic Percept™ RC neurostimulator as well as FDA approval of Asleep DBS for people with Parkinson’s disease or essential tremor and expanded MRI labeling - both exclusive to Medtronic DBS.

全球公认的MDS大会是在美敦力大脑调节取得重大进展的一年中举行的，其中包括美国食品和药物管理局（FDA）和CE（ConformitéEuropéenne）对美敦力Percept™RC神经刺激器的批准，以及FDA对帕金森病或原发性震颤患者睡眠DBS的批准，以及扩大的MRI标记-这两者都是美敦力DBS独有的。

Medtronic also recently announced the publication of its ADAPT-PD clinical trial methods manuscript. .

美敦力最近还宣布发布其ADAPT-PD临床试验方法手稿。。

Since 1987, Medtronic has served more than 185 thousand patients with movement disorders and other indications in more than 70 countries with its life-changing DBS therapy1.

自1987年以来，美敦力在70多个国家为超过18.5万名运动障碍和其他适应症患者提供了改变生活的DBS治疗1。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。。我们的使命是减轻痛苦，恢复健康，延长寿命，我们团结了150多个国家的95000多名充满激情的全球团队。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn..

随着我们增强洞察力驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们的期望会更高。在我们所做的每件事中，我们都在创造非凡。。。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性声明都会受到风险和不确定性的影响，例如美敦力向美国证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果存在重大差异。

Medtronic DBS therapy is approved for five indications: Parkinson's disease, essential tremor, dystonia, obsessive-compulsive disorder (OCD), and epilepsy. Indications vary by product. Refer to product labeling for details. Humanitarian device: The effectiveness of these devices for the treatment of dystonia or obsessive-compulsive disorder has not been demonstrated. .

美敦力DBS疗法被批准用于五种适应症：帕金森病，原发性震颤，肌张力障碍，强迫症（OCD）和癫痫。适应症因产品而异。有关详细信息，请参阅产品标签。人道主义设备：这些设备用于治疗肌张力障碍或强迫症的有效性尚未得到证实。。

References

参考文献

Medtronic data on file.

美敦力数据存档。

Contacts:

联系人：

Naomi Rodiles

娜奥米·罗迪莱斯

Public Relations

公共关系

+1-612-427-5521

+1-612-427-5521

Ryan Weispfenning

瑞安·韦斯芬宁

Investor Relations

投资者关系

+1-763-505-4626

+1-763-505-4626